Provider Review — May 2026
GLP-1 Telehealth — Streamlined Intake, Licensed Physician Oversight
Always confirm current pricing, availability, and terms directly with Direct Meds before enrolling.
Direct Meds has positioned itself as the efficiency-first option in the GLP-1 telehealth market. While programs like Enhance MD prioritize comprehensive medical oversight and Sprout Health emphasizes physician supervision across all 50 states, Direct Meds has built its platform around a single core value: getting eligible patients from interest to prescription as quickly and simply as possible without sacrificing the licensed physician oversight that responsible GLP-1 prescribing requires.
This approach serves a real patient need. The GLP-1 market expanded dramatically in 2022–2025, partly because patients discovered that the traditional path to obesity medication — securing a referral to an obesity medicine specialist, waiting months for an appointment, and navigating insurance prior authorization — was impractical for most people. Telehealth platforms like Direct Meds solved that access problem by creating streamlined pathways that maintain physician oversight while eliminating unnecessary friction.
The result is a platform well suited for patients who have already researched GLP-1 medications, understand the treatment protocol, know they are likely eligible, and simply want to get started as quickly as possible with a licensed physician managing their prescription.
GLP-1 medications — glucagon-like peptide-1 receptor agonists — work by mimicking a hormone naturally produced in the gut in response to food intake. This hormone signals the brain to reduce appetite, slows gastric emptying to increase feelings of fullness, and stimulates insulin release in a glucose-dependent manner. The combined effect is significantly reduced caloric intake over time, which produces meaningful weight loss when maintained consistently.
The STEP-1 clinical trial published in the New England Journal of Medicine in 2021 demonstrated an average body weight reduction of approximately 15% over 68 weeks with semaglutide — a result substantially greater than lifestyle intervention alone, which produced approximately 2.4% weight reduction in the same trial. Individual patient results vary significantly based on starting weight, adherence to the medication protocol, dietary habits, and individual metabolic response.
GLP-1 medications are administered as weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm. The injection process is straightforward and most patients become comfortable with self-administration within the first one to two doses. Medications are supplied with injection pens designed for ease of use, and your Direct Meds physician can walk you through the administration process during your consultation.
Standard GLP-1 eligibility criteria require a BMI of 30 or above — classified as obesity — or a BMI of 27 or above combined with at least one weight-related health condition. Common qualifying conditions include type 2 diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea. Your Direct Meds physician makes the final eligibility determination after reviewing your health history during the consultation process.
GLP-1 medications are not appropriate for everyone. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Patients with a history of pancreatitis, certain gastrointestinal conditions, or who are pregnant or planning to become pregnant should discuss these factors with their physician before starting treatment. The physician consultation at Direct Meds is designed to screen for these contraindications before any prescription is issued.
Direct Meds is particularly well suited for patients who are self-pay or uninsured and want a cost-accessible entry point, patients who have already discussed GLP-1 treatment with their regular physician and want a telehealth platform to manage the prescription and delivery, and patients for whom speed of access is the primary concern.
Direct Meds' pricing should be verified directly on their site before enrolling. As a performance-optimized platform designed for accessibility, their pricing is intended to make GLP-1 treatment reachable for self-pay patients. Confirm what is included in the monthly fee — medication, physician oversight, shipping — and what if any additional costs may apply before submitting payment.
For patients without insurance coverage, it is worth understanding that GLP-1 medication costs have shifted significantly in 2025–2026 following the end of widespread compounded GLP-1 availability. The pricing landscape is changing rapidly and verifying current rates directly with Direct Meds will give you the most accurate picture of what you will pay.
💡 Before enrolling: Ask Direct Meds specifically about what medication they currently prescribe — branded or compounded — and the pharmacy pathway. Given the FDA enforcement actions of 2025–2026, understanding this is an important part of making an informed enrollment decision.
Direct Meds is a solid choice for patients who prioritize speed and simplicity in accessing GLP-1 treatment. Their streamlined intake process and fast physician review make them the strongest option in our directory for patients who want to get started quickly. They are particularly well suited for self-pay patients looking for an accessible entry point and for patients who have already done their research and simply need a reliable platform to manage their prescription and delivery. Patients who want the most comprehensive medical oversight — including lab testing and access to both GLP-1 and GIP-GLP-1 medications — should consider Enhance MD instead.
Check current pricing, confirm state availability, and start your intake process on the Direct Meds platform.
Visit Direct Meds →⚠️ Affiliate Disclosure: Paragon Health Access is operated by Paragon Frontier Capital LLC and earns a commission if you enroll through this link. This does not affect the price you pay or our editorial assessment. All medical decisions are made by licensed Direct Meds physicians. This is not medical advice. Last reviewed May 2026.